Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients and 45 Tag SNPs in 7 Candidate Genes: A Prospective Study

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Bakker, P Roberto ^a   Al Hadithy, Asmar F Y ^b   Amin, Najaf ^b   van Duijn, Cornelia M ^b   van Os, Jim ^c,d   van Harten, Peter N ^a,c  

^a Psychiatric Centre GGZ Centraal   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DRD3 GENE; DRD4 GENE; DYSTONIA; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GRIN2A GENE; GRIN2B GENE; HSPG2 GENE; HTR2C GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NQO1 GENE; PARKINSONISM; PROSPECTIVE STUDY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84870748034     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050970     Document Type: Article

References (78)

1. Casey DE, (2006) Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 11: 25-31.
2. Lambert M, Conus P, Eide P, Mass R, Karow A, et al. (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19: 415-422.
3. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, et al. (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57: 209-219.
4. Lerer B (2002) Pharmacogenetics of psychotropic drugs. Cambridge, UK: Cambridge University Press.
5. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, et al. (2002) Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 181: 422-7.
6. McCreadie RG, Thara R, Srinivasan TN, Padmavathi R, (2003) Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br J Psychiatry 183: 45-49.
7. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, et al. (2001) Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 104: 375-379.
8. Fenton WS, (2000) Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 61 (Suppl 4): 10-4.
9. Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, et al. (2004) Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry 185: 465-471.
10. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, et al. (2010) Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull 36: 723-731.
11. Owens DGC (1999) A guide to the extrapyramidal side-effects of antipsychotic drugs. New York: Cambridge University Press UK.
12. Factor SA, Lang AE, Weiner WJ (2005) Drug induced movement disorders. Malden, Mass: Blackwell Futura.
13. Sachdev PS (2005) Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 28: 255-74, x.
14. Faraone SV, Tsuang MT, and Tsuang BW (1999) Genetic of mental disorders. New York: The Guilford Press.
15. Wellcome Trust Case Control Consortium, (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
16. Hemminki K, Forsti A, Bermejo JL, (2008) The 'common disease-common variant' hypothesis and familial risks. PLoS ONE 3: e2504.
17. Reich DE, Lander ES, (2001) On the allelic spectrum of human disease. Trends Genet 17: 502-510.
18. Wang WY, Barratt BJ, Clayton DG, Todd JA, (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6: 109-118.
19. Bakker PR, de Groot IW, van Os J, van Harten PN (2011) Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS ONE 6: e25588. 10.1371/journal.pone.0025588 [doi];PONE-D-11-04652 [pii].
20. van Harten PN, Matroos GE, Hoek HW, Kahn RS, (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res. 19: 195-203.
21. Guy W (1975) ECDEU assessment manual for psychopharmacology. In: Washington DC: Department of Health, Education and Welfare. 534-537.
22. Guy W (1976) ECDEU assessment manual for psychopharmacology. Rockville, Md: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
23. Fahn S, Elton R (1987) UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. In: Florham Park, NJ: Macmillan. 153-163.
24. Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, et al. (2009) Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol. 24: 123-128.
25. Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, et al. (2009) The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 23: 652-659.
26. Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, et al. (2008) Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 147B: 890-897.
27. StataCorp.2009. Stata: Release 11. Statistical Software. College Station, TX: StataCorp LP.
28. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B (2011) Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J. tpj201132 [pii];10.1038/tpj.2011.32 [doi].
29. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, et al. (2010) Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 35: 1155-1164. npp2009220 [pii];10.1038/npp.2009.220 [doi].
30. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, et al. (2008) Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 18: 317-323.
31. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, et al. (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27: 105-19.
32. Bakker PR, van Harten PN, van Os J, (2006) Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83: 185-192.
33. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, et al. (2009) Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33: 475-481.
34. Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, et al. (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96: 187-91.
35. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, et al. (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152: 408-413.
36. Segman RH, Heresco-Levy U, Yakir A, Goltser T, Strous R, et al. (2002) Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 51: 261-263.
37. Basile VS, Masellis M, Potkin SG, Kennedy JL, (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11: 2517-30.
38. Zhang ZJ, Zhang XB, Hou G, Yao H, Reynolds GP, (2003) Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr Genet 13: 187-192.
39. Zai CC, Tiwari AK, De Luca V, Muller DJ, Bulgin N, et al. (2009) Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 19: 317-328.
40. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, et al. (2006) Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 16: 111-117.
41. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E, (2004) Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 7: 489-493.
42. Zai CC, Tiwari AK, Basile V, De Luca V, Muller DJ, et al. (2009) Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J 9: 168-174.
43. Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP, (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7: 670-671.
44. Segman RH, Lerer B, (2002) Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 7: 137-139.
45. Gunes A, Dahl ML, Spina E, Scordo MG, (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64: 477-482.
46. Rizos EN, Siafakas N, Katsantoni E, Lazou V, Sakellaropoulos K, et al. (2009) Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet 19: 106-107.
47. Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, et al. (2004) Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 7: 495-500. 10.1017/S1461145704004419 [doi];S1461145704004419 [pii].
48. Xu Z, Taylor JA (2009) SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 37: W600-W605. gkp290 [pii];10.1093/nar/gkp290 [doi].
49. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39: 486-7.
50. Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer.
51. Ziegler A and König IR (2006) A statistical approach to genetic epidemiology: concepts and applications. Weinheim: Wiley-VCH.
52. Benjamini Y, Bretz F, and Sarkar SK (2004) Recent developments in multiple comparison procedures. Beachwood, Ohio: Institute of Mathematical Statistics.
53. Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, et al. (2012) Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS ONE 7: e36561. 10.1371/journal.pone.0036561 [doi];PONE-D-12-00737 [pii].
54. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120. S0002-9297(07)61949-1 [pii];10.1086/381000 [doi].
55. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35: 549-562. sbp006 [pii];10.1093/schbul/sbp006 [doi].
56. van Os J, Kenis G, Rutten BP, (2010) The environment and schizophrenia. Nature 468: 203-212.
57. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, et al. (2005) Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8: 411-425.
58. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 25: 2809-2817. 10.1002/mds.23377 [doi].
59. Tanaka S, Syu A, Ishiguro H, Inada T, Horiuchi Y, et al. (2011) DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics J. tpj201136 [pii];10.1038/tpj.2011.36 [doi].
60. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology Published online.
61. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, et al. (2010) Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67: 279-282.
62. Szklo M and Nieto FJ (2007) Epidemiology: beyond the basics. Sudbury, Mass: Jones and Bartlett Publishers.
63. Rothman KJ, Greenland S, and Lash TL (2008) Modern epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
64. Zammit S, Lewis G, Dalman C, Allebeck P (2010) Examining interactions between risk factors for psychosis. Br J Psychiatry 197: 207-211. 197/3/207 [pii];10.1192/bjp.bp.109.070904 [doi].
65. Kendler KS, Gardner CO (2010) Interpretation of interactions: guide for the perplexed. Br J Psychiatry 197: 170-171. 197/3/170 [pii];10.1192/bjp.bp.110.081331 [doi].
66. Zammit S, Owen MJ, Lewis G (2010) Misconceptions about gene-environment interactions in psychiatry. Evid Based Ment Health 13: 65-68. 13/3/65 [pii];10.1136/ebmh.13.3.65 [doi].
67. Rabe-Hesketh S and Skrondal A (2008) Multilevel and longitudinal modelling using stata. College Station, Tex: Stata Press.
68. Molenaar PCM, Campbell CG, (2009) The New Person-Specific Paradigm in Psychology. Current Directions in Psychological Science 18: 112-117.
69. Myin-Germeys I, Oorschot M, Collip D, Lataster J, Delespaul P, et al. (2009) Experience sampling research in psychopathology: opening the black box of daily life. Psychol Med 39: 1533-1547. S0033291708004947 [pii];10.1017/S0033291708004947 [doi].
70. Csikszentmihalyi M, Larson R, (1987) Validity and reliability of the Experience-Sampling Method. J Nerv Ment Dis 175: 526-536.
71. Myin-Germeys I, Birchwood M, Kwapil T (2011) From environment to therapy in psychosis: a real-world momentary assessment approach. Schizophr Bull 37: 244-247. sbq164 [pii];10.1093/schbul/sbq164 [doi].
72. Smith A, Balazinska M, Baru C, Gomelsky M, McLennan M, et al. (2011) Biology and data-intensive scientific discovery in the beginning of the 21st century. OMICS 15: 209-212. 10.1089/omi.2011.0006 [doi].
73. Chalise P, Batzler A, Abo R, Wang L, Fridley BL (2012) Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS 16: 363-373. 10.1089/omi.2011.0126 [doi].
74. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, et al. (2006) A road map for efficient and reliable human genome epidemiology. Nat Genet 38: 3-5.
75. Gunther T, Schmitt AO, Bortfeldt RH, Hinney A, Hebebrand J, et al. (2011) Where in the genome are significant single nucleotide polymorphisms from genome-wide association studies located? OMICS 15: 507-512. 10.1089/omi.2010.0154 [doi].
76. Braff DL, Freedman R, Schork NJ, Gottesman II, (2007) Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33: 21-32.
77. Koning JP, Tenback DE, Kahn RS, Van Schelven LJ, van Harten PN, (2010) Instrument measurement of lingual force variability reflects tardive tongue dyskinesia. J Med Eng Technol 34: 71-77.
78. Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, et al. (2012) Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 219: 727-736. 10.1007/s00213-011-2394-1 [doi].